Singapore Study Finds That Cancer Reprograms Neutrophils To Promote Tumor Growth!

Cancer News: In a groundbreaking research endeavor led by the ASTAR.Singapore Immunology Network (ASTAR.SIgN), scientists have delved into the intricacies of cancer biology, unveiling a previously unknown facet: the reprogramming of neutrophils to actively promote tumor growth. Neutrophils, the body's most abundant white blood cells, have long been recognized for their critical role in the immune system, adept at combating infections and safeguarding overall health. However, this new study brings to light a transformative process occurring within certain cancers, where neutrophils switch roles, supporting tumor growth instead of defending against it.


Tumor-infiltrating neutrophils undergo convergent reprogramming into pro-angiogenic neutrophils that support tumor growth. In cancer, both immature and mature neutrophils infiltrate the tumor. After entering the tumor microenvironment, these neutrophils undergo differentiation, leading to the formation of transitional populations. Through reprogramming, these populations ultimately converge into a terminal neutrophil state. Reprogrammed neutrophils strongly express VEGFα and localize to a unique hypoxic-glycolytic niche near the tumor core. This places them in an optimal position to exert their pro-angiogenic function within hypoxic and nutrient-poor tumor regions, thereby promoting tumor growth. The emergence of tumor reprogramming reflects the adaptability of neutrophils to environmental cues, allowing them to consolidate their protumoral responses.

The Study's Core Findings
The focal point of this groundbreaking study that is covered in this Cancer News report, was pancreatic cancer, utilizing an experimental pre-clinical model to dissect the contributions of different neutrophil states within the tumor microenvironment to tumor progression. The researchers identified three distinct neutrophil states - T1, T2, and T3 - each characterized by unique epigenetic and transcriptional profiles. Remarkably, T1 and T2 neutrophils, representing immature and mature states, respectively, underwent a reprogramming process that culminated in the emergence of a singular, long-lived T3 cell subset.
 
Decoding the Role of Reprogrammed Neutrophils in Tumor Growth
The crux of the discovery lies in the profound ability of reprogrammed T3 neutrophils to promote the growth of new blood vessels within the tumor core. This phenomenon proves indispensable for tumors, enabling them to overcome limitations in oxygen and nutrient supply. Targeting the vessel-promoting function of T3 neutrophils in pre-clinical models yielded promising results, leading to a reduction in the growth of pancreatic tumors. This revelation opens up a potential avenue for the development of novel therapeutic strategies that selectively target tumor-promoting neutrophils, offering a more precise approach compared to traditional methods that may indiscriminately deplete neutrophils.
 
Understanding the Intricacies of Neu trophil Reprogramming
To unravel the mechanisms by which disparate neutrophil states coordinate into a unified protumoral response, the study employed advanced techniques such as single-cell RNA sequencing and ATACseq (assay for transposable chromatin sequencing). The researchers observed that neutrophils infiltrating the tumor undergo deterministic reprogramming, adopting a common functional phenotype regardless of their initial maturation stage. This reprogramming process was characterized by the up-regulation of the surface marker dcTRAIL-R1.
 
The Wider Clinical Implications
Beyond the confines of the experimental model, the research team revisited and re-analyzed other published datasets in humans, uncovering similar instances of neutrophil reprogramming in certain solid cancers. Crucially, the T3 neutrophil signature predicted poorer patient outcomes in multiple human cancer cohorts, underscoring the clinical relevance of these findings. This insight opens up new vistas for therapeutic interventions targeting neutrophil reprogramming, potentially enhancing the efficacy of current cancer treatments and immunotherapies.
 
Navigating the Landscape of Cancer Immunotherapy
Dr Melissa Ng, a fellow at ASTAR.SIgN and co-corresponding author of the study, emphasized the significance of selectively targeting reprogrammed neutrophils. This targeted approach aims to diversify treatment options for human cancers, minimizing the impact of non-specific neutrophil targeting that may compromise the immune system's vital functions. Professor Lam Kong Peng, Executive Director at ASTAR.SIgN, underscored the pivotal role of breakthrough science in shaping the next generation of cancer immunotherapeutics. This groundbreaking study is poised to improve clinical outcomes for cancer patients not only in Singapore but globally.
 
Unveiling the Dynamics of Neutrophil Reprogramming
The study's methodology involved a meticulous examination of neutrophils in the context of their ontogeny, unveiling their intrinsic flexibility in adapting to environmental signals regardless of their initial maturation stage. This implies that neutrophils infiltrating a tissue niche follow a common path, merging their different functional states into a single terminal phenotype guided by the tissue. Within the tumor microenvironment, this deterministic program ensures a continual supply of pro-angiogenic T3 neutrophils, which, in turn, fuel tumor growth.
 
Implications for Future Research and Therapeutic Development
As research progresses, the team is committed to further investigating the factors that drive neutrophil reprogramming in human cancers. This exploration is pivotal for developing more effective ways to target and treat cancer through strategies focused on neutrophils. The study not only sheds light on the intricate interplay between neutrophils and tumors but also presents a promising avenue for future therapeutic approaches that target neutrophil reprogramming and their resultant functions.
 
The Future Landscape of Cancer Therapeutics
The potential therapeutic impact of this research lies in its ability to pave the way for more nuanced and targeted cancer therapies. By understanding the specific mechanisms behind neutrophil reprogramming and its role in supporting tumor growth, researchers can envisage strategies that disrupt this process, potentially enhancing the efficacy of existing cancer treatments and immunotherapies. The study's findings not only contribute to the scientific understanding of cancer biology but also offer tangible prospects for improving patient outcomes and refining the arsenal of tools available for oncologists in their battle against cancer.
 
Conclusion
In conclusion, this study represents a pivotal stride forward in unraveling the complexities of the immune system's interaction with cancer. The identification of a deterministic reprogramming process shines a light on how neutrophils dynamically adapt to the tumor microenvironment, providing a potential therapeutic target. The ability to selectively target tumor-promoting neutrophils while preserving normal neutrophil responses opens new avenues for enhancing the efficacy of cancer treatments. As research continues to unfold, the investigation into the factors driving neutrophil reprogramming in human cancers holds tremendous promise for the development of more effective strategies focused on neutrophils, ultimately advancing cancer therapies and improving patient outcomes on a global scale.
 
The study findings were published in the peer reviewed journal: Cancer Immunology (Science).
https://www.science.org/doi/10.1126/science.adf6493
 
For the latest Cancer News, keep on logging to Thailand Medical News